English (UK)
中文版Dr. Alex Zhang
Cross border life science accelerator and angel investor based in San Francisco Bay Area and Wuxi, China.
Hanhai Biolabs, Inc.
CEOAbby Zhang
大博医疗科技股份有限公司是一家A股上市的综合性医用高值耗材公司。立足于骨科产品的行业优势地位，现已是国内最具成长性的医用高值耗材企业之一。
Double Medical
Investment managerMr. Luc Zhang
High-throughput Human Disease and Tissue Models
MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
Responsive Web Design powered by 